Cardiovascular Disease Pipeline
Our pipeline products for cardiovascular disease, the most advanced of which is in phase 2 clinical development, have had significant investment to date in bringing them to their current stages of development.
Serious cardiovascular events including angina, myocardial infarction, sudden cardiac death and stroke have been shown to exhibit a pronounced circadian variation, with a marked peak in the morning hours when the patient assumes an upright posture and begins daily activities. Studies have demonstrated that many cardiovascular disorders occur with the greatest frequency between 4 am and 12 noon in the general population. Blood pressure is highest during the day and lowest during sleep with a rapid increase during the 4 am to 12 noon time period.
Circ has developed two cardiovascular products formulated to optimise their effect during waking hours and to minimise side effects, these products that can be administered in the evening with the onset beginning prior to waking the next morning would provide full coverage during waking hours.
Bisoprolol PM
Bisoprolol PM is a novel formulation of the beta-adrenergic blocking agent (beta blocker), bisoprolol. It is marketed at present in the US and Europe as an immediate release product, for the management of hypertension and in Europe also for the treatment of angina and CHD. The regulatory approval strategy for this product will be a 505(b)(2) NDA which may help shorten the development and approval times for this product.Read More>>
IS5MN PM
IS5MN PM is a novel formulation of Isosorbide-5-Mononitrate (IS5MN), an organic nitrate and the major biologically active metabolite of isosorbide dinitrate (ISDN), a vasodilator with effects on both arteries and veins. IS5MN is indicated for the treatment of angina pectoris, due to coronary artery disease.Read More>>
CRES Statins
Circ Pharma is developing a number of unique Controlled Release Enhanced Statin (CRES) product candidate formulations for the treatment of hypercholesterolemia with very significant revenue potential and market opportunity. Global sales of statins currently exceed $26 billion per annum.Read More>>